Literature DB >> 10508799

Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol.

R Dhand1, M Goode, R Reid, J B Fink, P J Fahey, M J Tobin.   

Abstract

The (R)-enantiomer of racemic albuterol produces bronchodilation, whereas the (S)-enantiomer may increase airway reactivity. After oral or intravenous administration of racemic albuterol, the (R)- enantiomer is metabolized several times faster than the (S)-enantiomer; however, enantiomer disposition after inhaling racemic albuterol with a metered-dose inhaler (MDI) is not known. Accordingly, 10 healthy subjects inhaled racemic albuterol with a MDI alone and with a MDI and holding chamber. We measured plasma levels of unchanged (R)- and (S)-albuterol before and up to 4 h after inhalation of racemic albuterol, and determined the unchanged R/S ratio in urine before and at 0.5, 4, 8, and 24 h later. The disposition of albuterol's enantiomers with a MDI and holding chamber was similar to that with a MDI alone. The area under the curve (AUC) of the plasma levels over time was significantly lower for the (S)- than for the (R)-enantiomer-395.5 +/- 141.0 (SE) versus 882.7 +/- 126.4 ng. ml(-)(1). min (p < 0.05)-indicating preferential retention of (S)-albuterol in the lung. The R/S ratio in urine at 0. 5 h after albuterol was > 1, reflecting the higher plasma level of the (R)-enantiomer. In conclusion, preferential retention of the (S)- compared with the (R)-enantiomer in the lung could lead to accumulation of the (S)-enantiomer after long-term use of racemic albuterol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508799     DOI: 10.1164/ajrccm.160.4.9812074

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  6 in total

Review 1.  The pharmacokinetics of levosalbutamol: what are the clinical implications?

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 2.  Beta2-agonists and bronchial hyperresponsiveness.

Authors:  Clive P Page; Domenico Spina
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

3.  Levalbuterol versus albuterol.

Authors:  Bill T Ameredes; William J Calhoun
Journal:  Curr Allergy Asthma Rep       Date:  2009-09       Impact factor: 4.806

4.  Acute severe asthma: new approaches to assessment and treatment.

Authors:  Spyros A Papiris; Effrosyni D Manali; Likurgos Kolilekas; Christina Triantafillidou; Iraklis Tsangaris
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Levalbuterol for asthma: a better treatment?

Authors:  H William Kelly
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

Review 6.  Single-isomer levalbuterol: a review of the acute data.

Authors:  Richard Nowak
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.